Hong Kong stock market anomaly | CRO concept stocks rebounded in early trading, with multiple CRO companies issuing clarification announcements. The government work report first mentioned "innovative drugs".

Zhitong App learned that the concept stocks of CRO rebounded in the morning session. As of the time of publication, VIVA BIOTECH (01873) rose by 5.05% to HKD 0.52; WUXI APPTEC (02359) rose by 4.11% to HKD 46.85; TIGERMED (03347) rose by 3.66% to HKD 25.5; PHARMARON (03759) rose by 3.89% to HKD 46.75; and WuXi Biologics (02269) rose by 3.16% to HKD 17.62.

On March 6, the U.S. Senate Homeland Security Committee held a proposal hearing, and the U.S. Senate version of the "Biological Security Act" (S3558) was overwhelmingly passed with consent votes. WUXI APPTEC and WuXi Biologics both issued announcements once again denying that the company poses a risk to national security in the United States or other countries, and they will continue to monitor developments. Pharmaron stated that its business operations continue as usual.

In addition, the government work report stated in the section "Actively Cultivating Emerging Industries and Future Industries" that it will consolidate and expand the leading advantages of industries such as intelligent connected new energy vehicles, accelerate the development of cutting-edge emerging industries such as hydrogen energy, new materials, and innovative drugs, and actively build new growth engines such as biomanufacturing, commercial aerospace, and low-altitude economy. It is worth noting that the term "innovative drugs" has entered the government work report for the first time, which may drive more domestic pharmaceutical companies to increase investment and focus on innovation.